PVALB and schizophrenia: None of our molecular measures showed any association with other variables of the study with the exception of parvalbumin, which showed an increase in the antipsychotic treated group compared to drug-free subjects (Table 4, Cohort I; Dunn’s Test p<0.05), indicating that the increase observed for parvalbumin in schizophrenia could be due to the antipsychotic treatments in these subjects.